Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | SCD | O00767 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186173 | 0.92 | MAPT (0.52) | PAX8MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL4401037 | 0.86 | RAB9A (0.46) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4396950 | 0.86 | RAB9A (0.47) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL4402161 | 0.86 | RAB9A (0.45) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL4397529 | 0.85 | MAPT (0.46) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL544203 | 0.85 | CSNK1D (0.50) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL5154824 | 0.84 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2RAB9APOLBMEN1 | |
| SCHEMBL4399543 | 0.83 | RAB9A (0.66) | PAX8MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL4396993 | 0.81 | ALDH1A1 (0.55) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4405589 | 0.80 | NPC1 (0.63) | MAPTGAASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | claimed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1745044-A2 | BENZOTHIAZOLE DERIVATIVES HAVING CDK MODULATING ACTIVITY AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097787-A2 | NOVEL BENZOTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | TFEB, ABAT, BRD4 | PAX8 2717/4885MAPT 355/4885GAA 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.